Academy of Physicians
in Clinical Research

Academy of Physicians
in Clinical Research




News from SCRIP

APCR Members can get a free trial to SCRIP and a discount on a SCRIP subscription by contacting John Lezcano from SCRIP directly at the information below. 

John Lezcano
Corporate Account Manager

Pharma intelligence | informa
T: (212) 652-2678
M: (631) 807-4971
John.lezcano@informa.com
pharmaintelligence.informa.com

Pharma Q3 Results Preview: Novartis, Lilly, Amgen, GSK

Fri, 10/20/2017 - 10:40am

There's optimism around Novartis as it heads into its final quarter with Joe Jimenez in charge, while Lilly faces impending...

      Related Stories 

Pharma Q3 Results Preview: Novartis, Lilly, Amgen, GSK

Fri, 10/20/2017 - 10:40am

There's optimism around Novartis as it heads into its final quarter with Joe Jimenez in charge, while Lilly faces impending...

      Related Stories 

Celgene IBD Pipeline In Question As Mongersen Crohn’s Disease Trial Ends

Fri, 10/20/2017 - 10:34am

Celgene will stop late-stage testing of its investigative therapy mongersen for Crohn’s disease after a data monitoring committee said it...

      Related Stories 

Celgene IBD Pipeline In Question As Mongersen Crohn’s Disease Trial Ends

Fri, 10/20/2017 - 10:34am

Celgene will stop late-stage testing of its investigative therapy mongersen for Crohn’s disease after a data monitoring committee said it...

      Related Stories 

Deal Watch: Syndax Gets Former Vitae Leukemia Program From Allergan

Fri, 10/20/2017 - 8:54am

Cancer-focused biotech obtains preclinical program aimed at leukemia subset involving chromosomal rearrangements. Merck acquires an interest in KalVista and rights...

      Related Stories 

Deal Watch: Syndax Gets Former Vitae Leukemia Program From Allergan

Fri, 10/20/2017 - 8:54am

Cancer-focused biotech obtains preclinical program aimed at leukemia subset involving chromosomal rearrangements. Merck acquires an interest in KalVista and rights...

      Related Stories 

Opdivo Use For Urothelial Cancer Blocked By NICE In Draft Guidance

Fri, 10/20/2017 - 7:20am

Opdivo has failed to convince the UK's pricing watchdog, NICE, of its value and benefit for patients with advanced urothelial...

      Related Stories 

Fosun Kite Bets On Cell Therapy Despite Approval Pathway Lag In China

Fri, 10/20/2017 - 6:53am

The approval of Kite's Yescarta has ignited Chinese drug maker Fosun. With a joint venture with Kite in place, the...

      Related Stories 

Amgen & Simcere Plot Long Run On Biosimilars In China

Fri, 10/20/2017 - 6:48am

The strategic alliance between Amgen and Simcere Pharmaceutical to develop biosimilars in China was officially kicked off in Nanjing city...

      Related Stories 

Amgen & Simcere Plot Long Run On Biosimilars In China

Fri, 10/20/2017 - 6:48am

The strategic alliance between Amgen and Simcere Pharmaceutical to develop biosimilars in China was officially kicked off in Nanjing city...

      Related Stories 

Novo's Semaglutide: Retinopathy Warning Unlikely To Dim Commercial Prospects

Thu, 10/19/2017 - 6:42pm

Sponsor's proposal for a label warning, but not a black box, on retinopathy risk with the once-weekly GLP-1 agonist finds...

      Related Stories 

UniQure Hemophilia B Gene Therapy Changes Ignite A Race To Market

Thu, 10/19/2017 - 2:06pm

UniQure is switching the gene therapy it plans to move into a pivotal trial in hemophilia B patients because the...

      Related Stories 

$500m And Counting: Vir Puts Big Money To Work In Infectious Diseases

Thu, 10/19/2017 - 2:06pm

Vir Biotechnology launched in January with $150m and a focus on infectious diseases. Now, the George Scangos-led venture has raised...

      Related Stories 

$500m And Counting: Vir Puts Big Money To Work In Infectious Diseases

Thu, 10/19/2017 - 2:06pm

Vir Biotechnology launched in January with $150m and a focus on infectious diseases. Now, the George Scangos-led venture has raised...

      Related Stories 

Scrip Asks… What's The Current Climate For Deal-Making? (Part 2)

Thu, 10/19/2017 - 10:44am

Following Gilead's acquisition of Kite, buzz grew that the deal might catalyze a surge in deal-making. Scrip asked a broad...

      Related Stories 

Scrip Asks… What's The Current Climate For Deal-Making? (Part 2)

Thu, 10/19/2017 - 10:44am

Following Gilead's acquisition of Kite, buzz grew that the deal might catalyze a surge in deal-making. Scrip asked a broad...

      Related Stories 

Pages